Todd T Brown1, Carlee Moser2, Judith S Currier3, Heather J Ribaudo2, Jennifer Rothenberg4, Theodoros Kelesidis3, Otto Yang3, Michael P Dubé5, Robert L Murphy6, James H Stein7, Grace A McComsey8. 1. Johns Hopkins University, Baltimore, Maryland. 2. Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts. 3. David Geffen School of Medicine, University of California-Los Angeles. 4. Social and Scientific Systems, Washington D.C. 5. Keck School of Medicine, University of Southern California, Los Angeles, California. 6. Feinberg School of Medicine, Northwestern University, Chicago, Illinois. 7. University of Wisconsin School of Medicine and Public Health, Madison. 8. Case Western Reserve University School of Medicine, Cleveland, Ohio.
Abstract
BACKGROUND:Specific antiretroviral therapy (ART) medications and the severity of human immunodeficiency virus (HIV) disease before treatment contribute to bone mineral density (BMD) loss after ART initiation. METHODS: We compared the percentage change in BMD over 96 weeks in 328 HIV-infected, treatment-naive individuals randomized equally to tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) plus atazanavir/ritonavir (ATV/r), darunavir/ritonavir (DRV/r), or raltegravir (RAL). We also determined whether baseline levels of inflammation markers and immune activation were independently associated with BMD loss. RESULTS: At week 96, the mean percentage changes from baseline in spine and hip BMDs were similar in the protease inhibitor (PI) arms (spine: -4.0% in the ATV/r group vs -3.6% in the DRV/r [P = .42]; hip: -3.9% in the ATV/r group vs -3.4% in the DRV/r group [P = .36]) but were greater in the combined PI arms than in the RAL arm (spine: -3.8% vs -1.8% [P < .001]; hip: -3.7% vs -2.4% [P = .005]). In multivariable analyses, higher baseline concentrations of high-sensitivity C-reactive protein, interleukin 6, and soluble CD14 were associated with greater total hip BMD loss, whereas markers of CD4(+) T-cell senescence and exhaustion (CD4(+)CD28(-)CD57(+)PD1(+)) and CD4(+) T-cell activation (CD4(+)CD38(+)HLA-DR(+)) were associated with lumbar spine BMD loss. CONCLUSIONS:BMD losses 96 weeks after ART initiation were similar in magnitude among patients receiving PIs, ATV/r, or DRV/r but lowest among those receiving RAL. Inflammation and immune activation/senescence before ART initiation independently predicted subsequent BMD loss.
RCT Entities:
BACKGROUND: Specific antiretroviral therapy (ART) medications and the severity of human immunodeficiency virus (HIV) disease before treatment contribute to bone mineral density (BMD) loss after ART initiation. METHODS: We compared the percentage change in BMD over 96 weeks in 328 HIV-infected, treatment-naive individuals randomized equally to tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) plus atazanavir/ritonavir (ATV/r), darunavir/ritonavir (DRV/r), or raltegravir (RAL). We also determined whether baseline levels of inflammation markers and immune activation were independently associated with BMD loss. RESULTS: At week 96, the mean percentage changes from baseline in spine and hip BMDs were similar in the protease inhibitor (PI) arms (spine: -4.0% in the ATV/r group vs -3.6% in the DRV/r [P = .42]; hip: -3.9% in the ATV/r group vs -3.4% in the DRV/r group [P = .36]) but were greater in the combined PI arms than in the RAL arm (spine: -3.8% vs -1.8% [P < .001]; hip: -3.7% vs -2.4% [P = .005]). In multivariable analyses, higher baseline concentrations of high-sensitivity C-reactive protein, interleukin 6, and soluble CD14 were associated with greater total hip BMD loss, whereas markers of CD4(+) T-cell senescence and exhaustion (CD4(+)CD28(-)CD57(+)PD1(+)) and CD4(+) T-cell activation (CD4(+)CD38(+)HLA-DR(+)) were associated with lumbar spine BMD loss. CONCLUSIONS: BMD losses 96 weeks after ART initiation were similar in magnitude among patients receiving PIs, ATV/r, or DRV/r but lowest among those receiving RAL. Inflammation and immune activation/senescence before ART initiation independently predicted subsequent BMD loss.
Authors: Y T Teng; H Nguyen; X Gao; Y Y Kong; R M Gorczynski; B Singh; R P Ellen; J M Penninger Journal: J Clin Invest Date: 2000-09 Impact factor: 14.808
Authors: C Scheidt-Nave; H Bismar; G Leidig-Bruckner; H Woitge; M J Seibel; R Ziegler; J Pfeilschifter Journal: J Clin Endocrinol Metab Date: 2001-05 Impact factor: 5.958
Authors: Joel E Gallant; Schlomo Staszewski; Anton L Pozniak; Edwin DeJesus; Jamal M A H Suleiman; Michael D Miller; Dion F Coakley; Biao Lu; John J Toole; Andrew K Cheng Journal: JAMA Date: 2004-07-14 Impact factor: 56.272
Authors: Joseph D Perazzo; Allison R Webel; S M Khurshid Alam; Abdus Sattar; Grace A McComsey Journal: J Assoc Nurses AIDS Care Date: 2018-03-28 Impact factor: 1.354
Authors: Theodoros Kelesidis; Carlee Moser; James H Stein; Todd T Brown; Thuy Tien T Tran; Heather J Ribaudo; Michael P Dube; Otto O Yang; Judith S Currier; Grace A McComsey Journal: J Infect Dis Date: 2016-06-28 Impact factor: 5.226
Authors: Kristine M Erlandson; Jordan E Lake; Myung Sim; Julian Falutz; Carla M Prado; Ana Rita Domingues da Silva; Todd T Brown; Giovanni Guaraldi Journal: J Acquir Immune Defic Syndr Date: 2018-03-01 Impact factor: 3.731
Authors: A Carr; B Grund; A V Schwartz; A Avihingsanon; S Badal-Faesen; J I Bernadino; V Estrada; A La Rosa; Pwg Mallon; S Pujari; D White; N Wyman Engen; K Ensrud; J F Hoy Journal: HIV Med Date: 2019-10-23 Impact factor: 3.180
Authors: Ighovwerha Ofotokun; Kehmia Titanji; Cecile D Lahiri; Aswani Vunnava; Antonina Foster; Sara E Sanford; Anandi N Sheth; Jeffrey L Lennox; Andrea Knezevic; Laura Ward; Kirk A Easley; Philip Powers; M Neale Weitzmann Journal: Clin Infect Dis Date: 2016-05-18 Impact factor: 9.079